NCT04466735

BRain Energy Activation With Ketones to Prevent Alzheimer's Disease

Name: Clinical Trial NCT04466735
Creator: Université de Sherbrooke
Keywords: MCI, Active group, Phase 2, dietary supplement, clinical trial, Canada

6 Month Randomized Controlled Trial With D-beta-hydroxybutyrate in Mild Cognitive Impairment

Université de Sherbrooke·Phase 2·ClinicalTrials.gov·dietary supplementRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: MCI
Drug/Device/Intervention: Active group
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: Université de Sherbrooke
Location: Sherbrooke, Canada

Timeline & enrollment

Phase: Phase 2
Start date: Oct 15, 2020
End date: Jul 01, 2023
Enrollment: 56 participants

Primary outcome

Acetoacetate brain uptake,Glucose brain uptake

Summary

A six month randomized controlled intervention with an exogenous ketone salt (EKS) supplement in mild cognitive impairment. Participants will receive 15 g of the supplement twice daily (equivalent to 24 g/day of EKS). Outcomes: brain energy metabolism, cognition, plasma biomarkers, brain imaging (volumetric, functional, structural) and quality of life will be analyzed before and after the intervention.

ICD-10 classifications

Microtia

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04466735
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04466735 through Pure Global AI's free database. This Phase 2 trial is sponsored by Université de Sherbrooke and is currently Recruiting. The study focuses on MCI. Target enrollment is 56 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.